Skip to main content

Gilead Sciences Tecartus revenue

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Tecartus revenue at Gilead Sciences came to $60.0M for the quarter to 30 Sep 2026, down 27.7% from a year earlier.

As Gilead Sciences reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$98.0MDec 2023$100.0MMar 2024$107.0MJun 2024$98.0MSep 2024$98.0MDec 2024$78.0MMar 2025$92.0MJun 2025$83.0MSep 2025$90.0MDec 2025$75.0MMar 2026$70.0MJun 2026$60.0MSep 2026
Gilead Sciences Tecartus revenue, every reported period
Period endingTecartus revenueChange on a yearFiled
30 Sep 2026$60.0Mdown 27.7%30 Oct 2026
30 Jun 2026$70.0Mdown 23.9%6 Aug 2026
31 Mar 2026$75.0Mdown 3.8%7 May 2026
31 Dec 2025$90.0Mdown 8.2%24 Feb 2026
30 Sep 2025$83.0Mdown 15.3%7 Nov 2025
30 Jun 2025$92.0Mdown 14.0%7 Aug 2025
31 Mar 2025$78.0Mdown 22.0%7 May 2025
31 Dec 2024$98.0Munchanged28 Feb 2025
30 Sep 2024$98.0Mup 2.1%12 Nov 2024
30 Jun 2024$107.0Mup 21.6%8 Aug 2024
31 Mar 2024$100.0Mup 12.4%8 May 2024
31 Dec 2023$98.0Mup 19.5%23 Feb 2024
30 Sep 2023$96.0Mup 18.5%7 Nov 2023
30 Jun 2023$88.0Mup 20.5%4 Aug 2023
31 Mar 2023$89.0Mup 41.3%3 May 2023
31 Dec 2022$82.0Mup 43.9%22 Feb 2023
30 Sep 2022$81.0Mup 72.3%2 Nov 2022
30 Jun 2022$73.0Mup 78.0%8 Aug 2022
31 Mar 2022$63.0Mup 103.2%4 May 2022
31 Dec 2021$57.0M—23 Feb 2022
30 Sep 2021$47.0Mup 422.2%3 Nov 2021
30 Jun 2021$41.0M—5 Aug 2021
31 Mar 2021$31.0M—6 May 2021
30 Sep 2020$9.0M—4 Nov 2020
30 Jun 2020$1.0M—6 Aug 2020
31 Mar 2020$0—6 May 2020

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Gilead Sciences: Product sales · Biktarvy revenue · Descovy revenue · Trodelvy revenue · Genvoya revenue · Vemlidy revenue · Yeztugo revenue · Yescarta revenue · Odefsey revenue · Sofosbuvir/Velpatasvir revenue · Livdelzi revenue · Symtuza - Revenue share revenue · AmBisome revenue · Veklury revenue · Royalty, contract and other revenues · United States revenue · Europe revenue · Rest of World revenue · financial statements

Every KPI and segment of GILD, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.